INBX Stock Summary and Trading Ideas (Inhibrx Biosciences | NASDAQ:INBX)

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Inhibrx Biosciences trades on the NASDAQ stock market under the symbol INBX.

As of October 6, 2026, INBX stock price declined to $93.41 with 146,799 million shares trading.

INBX has a beta of 3.02, meaning it tends to be more sensitive to market movements. INBX has a correlation of 0.17 to the broad based SPY ETF.

INBX has a market cap of $1.37 billion. This is considered a Small Cap stock.

In the last 3 years, INBX traded as high as $155.29 and as low as $10.80.

The top ETF exchange traded funds that INBX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.

INBX has outperformed the market in the last year with a return of +162.0%, while the SPY ETF gained +17.6%. However, in the most recent history, INBX shares have underperformed the stock market with its stock returning -4.3% in the last 3 month period and -16.6% for the last 2 week period, while SPY has returned +4.9% and +0.7%, respectively.

INBX support price is $89.60 and resistance is $99.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INBX shares will trade within this expected range on the day.